Supernus and Indivior Merge in All-Stock Deal to Build $2.2B CNS Powerhouse

What Happened

Supernus Pharmaceuticals (NASDAQ: SUPN) and Indivior Pharmaceuticals (NASDAQ: INDV) announced a definitive agreement to merge in a tax-free all-stock transaction on August 3, 2026. The combined company, to be named Supernus, Inc. and listed on Nasdaq under the ticker SUPN, will have approximately $2.2 billion in pro forma annual revenue and a portfolio of 11 approved central nervous system drugs spanning psychiatry, neurology, and addiction medicine.

The deal is structured as a merger of equals. Under the terms, Supernus stockholders will receive 1.5401 Indivior common shares for each Supernus share they own. Based on the August 1 closing prices (SUPN at $44.63, INDV at $40.01 from Polygon), that exchange ratio implies approximately $61.62 per Supernus share, a premium of roughly 38% over Supernus’s last close. Indivior stockholders will also receive a one-time special cash dividend of $1.0 billion in aggregate immediately prior to closing. Upon close, Indivior stockholders will own approximately 56.5% of the combined company and Supernus stockholders approximately 43.5%. (Supernus/Indivior joint press release via GlobeNewswire)

The Numbers

Metric	Value
Structure	All-stock merger of equals, tax-free
Exchange ratio	1.5401 INDV shares per SUPN share
Implied SUPN premium	~38% over $44.63 close
Special dividend to INDV holders	$1.0 billion (funded by $650M debt + cash)
Combined pro forma revenue	~$2.2 billion
Combined adjusted EBITDA	~$888 million (including synergies)
Targeted cost synergies	$125 million annually
Combined net debt	~$878 million
Approved drugs in portfolio	11
Ownership split	INDV 56.5% / SUPN 43.5%
Expected close	Q4 2026

Supernus brings a neuroscience portfolio covering ADHD, Parkinson’s disease dyskinesia, postpartum depression, epilepsy, migraine, and cervical dystonia. Indivior is the leader in long-acting injectable treatments for opioid use disorder (OUD), with its Sublocade franchise anchoring the addiction medicine side. The combined entity will have 11 differentiated CNS medicines, with key growth products expected to continue growing into the 2030s.

Why It Matters

The merger consolidates two mid-cap CNS players into a company with the scale to compete for business development deals and pipeline investment. The $125 million in targeted annual cost synergies, plus a net debt ratio below 1x, give the combined company financial firepower to pursue additional acquisitions or license late-stage assets. Jack Khattar, Supernus’s CEO, will lead the combined company, with Indivior board member Tony Kingsley serving as board chair.

The special dividend structure is notable. Indivior stockholders receive $1.0 billion in cash before the merger closes, funded by a $650 million term loan from Citibank and existing cash on the balance sheet. This effectively returns capital to Indivior holders while still giving them majority equity in the combined company. Supernus holders get a stock premium and participation in the combined entity’s growth.

The deal also reflects broader biopharma consolidation trends in 2026, with M&A pace on track to top $240 billion as patent cliffs drive dealmaking. CNS has been an active area, with several mid-cap combinations this year.

What to Watch Next

The transaction is expected to close in Q4 2026, subject to stockholder approvals from both companies, regulatory clearances, and customary closing conditions. Watch for the S-4 registration statement filing, potential competing bids for either company, and regulatory scrutiny given the overlap in CNS market positions. Supernus and Indivior will host a joint conference call at 8:30 AM EDT today to discuss the transaction alongside their Q2 2026 earnings.

What It Means for the Trade

This is a scale story wearing a merger-of-equals costume, and the trade runs on three numbers: the ~38% implied premium for SUPN holders, the $1.0 billion special dividend extracting cash from Indivior before close, and the $125 million in annual cost synergies funding the combined pipeline. The strategic logic is consolidation arithmetic — two mid-caps with a combined ~$2.2 billion revenue base and ~$888 million adjusted EBITDA get the balance-sheet scale to bid for late-stage CNS assets neither could buy alone, at a moment when patent cliffs are driving $240 billion in industry dealmaking. The 56.5/43.5 ownership split and the Kingsley chair give Indivior operational equilibrium, but Jack Khattar running the company means Supernus’s commercial machine leads integration. Watch the mechanics between now and Q4: the S-4 filing’s pro forma details, both shareholder votes (mergers of equals can wobble on either side), and antitrust review given overlapping neurology portfolios — though the therapeutic-area spread across psychiatry, addiction, epilepsy, and movement disorders argues the overlap is complementary rather than exclusionary.

Mechanism and Market Context

The portfolio logic is complementary revenue clocks. Indivior’s Sublocade franchise — long-acting injectable buprenorphine for opioid use disorder — sits in a structural growth market: addiction treatment demand is policy-driven and expanding, and monthly depot dosing converts a chronic adherence problem into a pharmacy-administered event. Supernus brings ADHD, epilepsy, migraine, postpartum depression, and Parkinson’s dyskinesia — specialty niches with branded pricing and long tails into the 2030s, per the companies’ guidance. The combined 11-drug portfolio is diversified enough that no single patent cliff is existential, and net debt below 1x EBITDA leaves room for the business-development strategy that motivated the deal. The CNS field’s consolidation wave reflects a broader truth: mid-cap specialty pharma has been squeezed between big-pharma scale and biotech innovation, and combinations are the fastest route to the deal-making heft needed to license or acquire late-stage assets — this merger is a case study of that logic, with the special dividend a pre-close sweetener for Indivior holders accepting majority ownership of an integration they do not control.

Risks and What Could Go Wrong

1. Merger-of-equals structures can stall at either shareholder vote; the 38% premium helps SUPN holders, but INDV holders are trading cash out the door for equity in an integration they do not lead.
2. $125 million in synergies typically costs real disruption — salesforce overlap and infrastructure cuts can dent launch execution on both sides’ growth products.
3. Antitrust review of overlapping CNS portfolios could force divestitures or delay the Q4 close.
4. Integration risk sits on top of existing business risk — Sublocade’s growth and Supernus’s launch products must each keep performing while management attention is on the merger.